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ABSTRACT 
 
 Proteoglycans located in basement membranes, the thin structures enveloping epithelial and 
endothelial layers, are unique in several respects. They are usually large elongated molecules with 
a collage of domains that share structural and functional homology with numerous extracellular 
matrix proteins, growth factors and surface receptors. They mainly carry heparan sulphate side 
chains and these contribute not only in storing and preserving the biological activity of various 
heparan sulfate-binding cytokines and growth factors, but also in presenting them in a more “active 
configuration” to their cognate receptors. Abnormal expression or deregulated function of these 
proteoglycans affect cancer and angiogenesis, and are critical for the evolution of the tumor 
microenvironment. This review will focus on the functional roles of the major three heparan 
sulphate proteoglycans from basement membranes, perlecan, agrin and collagen XVIII, and their 
roles in modulating cancer growth and angiogenesis.   
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Introduction 
Basement membrane proteoglycans comprise a selected group of high molecular-weight proteins 
which are almost universally decorated with heparan sulfate side chains {2232}. Three main 
basement membrane heparan sulfate proteoglycans (HSPGs) have been well characterized. The 
first identified HSPG of basement membranes is perlecan, a modular proteoglycan with homology 
to growth factors and proteins involved in cell growth, lipid metabolism, adhesion, and homo- and 
hetero-typic interactions {1082}. Collagen XVIII is a hybrid collagen/proteoglycan and a member of 
the multiplexin gene family together with the closely related collagen XV, which bears chondroitin 
sulfate side chains instead of HS chains {2388}. The third HSPG is agrin, an abundant constituent 
of most basement membranes with a specialized function at the neuromuscular junction {2208}. 
The genes encoding these three HSPGs protein cores are highly conserved and carry disparate 
biological functions, from maintenance of basement membrane homeostasis to modulation of 
growth factor activity and angiogenesis. Moreover, some of these gene products are expressed in 
avascular tissues, such as cartilage, and in musculoskeletal and nervous tissues, where they 
modulate neuronal transmission and ocular development. Defects in some of these genes cause 
various human inherited disorders and often the disease phenotypes correlate well those of mutant 
mice, flies and worms.  
 An emerging body of work supports the concept that these HSPGs have a dual function as pro- 
and anti-angiogenic factors {1779}. Via their N-terminal HS chains, they can stimulate angiogenic 
signaling by sequestering (i.e. concentrating) HS-binding growth factors such as FGF2, VEGF and 
PDGF, where they present them in a “biologically active” form to their cognate receptors.   
Alternatively, via proteolytic processing of their C-termini, these gene products can release 
powerful angiostatic fragments such as endostatin and endorepellin, which can act on a paracrine 
function on sprouting endothelial cells, either locally or distantly. 
 This review will focus primarily on these three basement membrane HSPGs and will critically 
assess recent information related to their roles in regulating cancer growth and angiogenesis.  
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Perlecan, a multimodular and multifunctional proteoglycan 
The designation for “perlecan” originates from studies using rotary shadowing electron microscopy 
which have shown a tortuous linear polymer with interspersed globular domains resembling a 
“string of pearls” {25,137}. Perlecan is a modular HSPG and is one of the largest single-chain 
polypeptides found in vertebrate and invertebrate animals {143, 193, 1082}. The five modules of 
perlecan are collated from protein units evolutionarily related to molecules involved in cell growth, 
lipid uptake and metabolism, intercellular interactions and adhesion (Fig.1). The perlecan’s protein 
is ~470 kDa and, together with several O-linked oligosaccharides and as many as four HS chains, 
three in domain I and one potential in domain V {812, 1682, 1673}, it can reach a molecular weight 
of over 800 kDa.  An intriguing question on perlecan’s evolutionary biology which has been 
recently raised {3149} is: What is the advantage of linking 44 different protein modules into a 
gigantic polypeptide over the synthesis of individual protomers? Perhaps, the answer lies on the 
generation of a protein scaffold, i.e. long heterofunctional protein. The large size of perlecan’s 
protein core which spans ~200 nm in length together with the three HS chains, which could span 
an additional 6o nm in  three dimension, make perlecan an appropriate linkage between 
extracellular matrix and cell surface receptors or complexes of receptors. The various modules of 
perlecan and the HS chains have a large repertoire of molecular interactions that include 
association with numerous heparin-binding growth factors such as FGF2, VEGF and PDGF {603, 
1419, 2934, 1838, 3059, 3060}, and other proteins which are constituents of basement membranes 
{2647, 2472}. Perlecan can also be associated with the cell surface {53, 1909} via high-affinity 
interactions with integrins, especially α2β1, the main surface receptor for fibrillar collagen {2432}.  
Agrin 
 
Collagen XVIII 
 
Basement membrane proteoglycans and angiogenesis 
Perlecan binds to many growth factors, and particularly those from the fibroblast growth factor 
family, known regulators of neovascularization {3424}.  It has been shown that the HS chains are 
responsible for the binding to FGF1, 2, 7, 9, 10, 18 {109, 580, 1555, 1610, 1675, 1901} and FGF-
binding protein {1707}, and such interactions may lead to enhanced angiogenesis and 
chondrogenesis.  Most of the research performed on the binding of perlecan to growth factors has 
concentrated on FGFs because of the availability of good research tools including recombinant 
growth factors and their receptors, antibodies, and the Baf32 cell line that has been transfected 
with the genes for the various FGFR isoforms {1675}.  The other point about FGFs is that they are 
produced by many cell types and in most cases signal cells to proliferate {3412}, although there 
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are some notable exceptions, such as FGF9 {3417} and FGF18 {3418, 3419} signaling through 
FGFR3 on chondrocytes. This is not caused by an inability of FGF9 to induce cell proliferation 
since it is indeed mitogenic when delivered via human chondrocyte perlecan to Baf32 cells 
expressing FGFR3c {2928}. These results suggest that FGF bioactivity is strongly influenced by 
the contextual environment in which the growth factor is presented, and expand the repertoire of 
subtle variations and sometimes paradoxical effects perlecan can display in particular pericellular 
environments {2934}. 
 Perlecan is also involved in the binding and bioactivity of FGF7, also known as keratinocyte 
growth factor. Colon carcinoma cells, in which the perlecan gene is disrupted by targeted 
homologous recombination, grow slowly, fail to respond to exogenous FGF7 with or without 
heparin and are less tumorigenic when injected in immunocompromised mice {1788}. In an 
engineered human skin model, perlecan-deficient keratinocytes form a poorly-organized epidermis 
which is partially restored by exogenous FGF7 {2798}. Finally, the protein core of perlecan binds to 
FGF18, a key factor for chondrogenesis, and alters the mitogenic effect of FGF18 on growth plate 
chondrocytes {3221}. This finding is also supported by the similarity in cartilage phenotype 
between perlecan null and the FGF18 null mice which both exhibit a defect in endochondral 
ossification {2136}.   
 All of these results need to be confirmed in vivo but support the hypothesis that perlecan is an 
inactive sink for FGFs; this would partly explain the reason why cells that are surrounded by 
perlecan and produce FGF do not proliferate out of control.  Instead, they remain in a quiescent 
state unresponsive to many mitogenic signals.  Whereas HS chains favor FGF/FGFR interaction, 
chondroitin sulfate chains in perlecan could act as “negative” regulators of FGF/FGFR activity, 
primarily by physically constraining the FGFs from contacting their cognate receptors.  It would be 
of interest to determine the structure of the HS attached to the different perlecan species in order 
to determine the specific microdomain structures that are responsible for mediating these various 
signals.   
Perlecan expression correlates with a more aggressive malignant phenotype {172}.Perlecan is 
highly expressed in the stroma of various tumors {111, 447}, and is often associated with the 
microvasculature which provides nutrients and oxygen to the growing neoplastic cells {2752}.  In 
1994 we reported the first evidence that perlecan could be involved in angiogenesis. We found that 
in tumor xenografts composed of human-derived prostate carcinoma cells and mouse-derived 
stromal elements, perlecan secreted by the human prostate cancer cells was deposited along the 
newly-formed (angiogenic) vessels of the tumor xenografts {193}. Thus, we hypothesized that 
perlecan might directly contribute to the scaffolding of angiogenic blood vessels. Nearly 
concurrently, it was demonstrated that perlecan is the major co-factor for the activity of FGF2 
{109}, a powerful angiogenic factor {1610}, and for the specific interaction with its cognate receptor 
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leading to enhanced mitogenesis and angiogenesis {109}.  The key contribution of tumor-derived 
perlecan to angiogenesis has been recently confirmed and extended in an epidermal tumor 
xenograft model {2383}. Notably, antisense targeting of endogenous perlecan in a variety of 
transformed cells including colon carcinoma and melanoma cells causes a significant inhibition of 
tumor growth and angiogenesis {837, 1563, 1369}. Ribozyme-mediated knockdown of perlecan 
gene expression in metastatic prostate carcinoma cells causes a reduced tumor growth rate, 
attenuated vascularization and reduced levels of VEGF {2839}. Seemingly, colon carcinoma cells 
with a somatic cell mutation leading to a perlecan null phenotype show growth retardation and 
minimal angiogenesis in tumor xenografts {1788}. The central role of perlecan in angiogenesis is 
further confirmed by genetic manipulation leading to complete ablation of the perlecan gene {1580, 
1585}. In addition to cartilage abnormalities, it was soon realized that perlecan deficiency was 
incompatible with adult life due primarily to the failure of blood vessels; most of the embryos die by 
day 11.5 of embryonic life due to pericardial hemorrhage, exactly at the time when cardiovascular 
circulation starts to fully develop and the intracardiac blood pressure suddenly rises.  Moreover, a 
significant proportion of perlecan-null mice develop numerous vascular anomalies including 
transposition of the great arteries and abnormal coronary arteries {1872, 2078}. In an animal model 
expressing a mutated form of perlecan lacking the canonical glycosaminoglycan attachment site, 
and thus lacking HS side chains, there is impaired angiogenesis and retarded tumor growth {2337}. 
Lack of HS-containing perlecan causes increased intimal hyperplasia and smooth muscle cell 
proliferation {2225}, whereas perlecan is required to inhibit thrombosis in an animal model of deep 
vascular injury {1647}. A recent study adds a new dimension to these results because it 
demonstrates that regulation of perlecan gene expression is regulated by a mechano-transduction 
pathway in endothelial cells and that this is a key mechanism through which endothelial cells inhibit 
vascular smooth muscle cell proliferation in response to changes in mechanical environment 
{3436}.   
Recently, a viable mutant animal has been generated in which exon 3 (Hspg2∆3/ ∆3), which 
contains two of the three possible HS attachment sites in domain I, has been deleted, thereby 
generating a markedly reduced amount of perlecan-attached HS chains {1912}. The mice exhibit 
small eyes with degeneration of the lens within 3 weeks of birth, a process accelerated in a double 
Col18a1-/- x Hspg2∆3/∆3 mutant background {1912}. Various experimental challenges of these HS-
deficient animals result in increased intimal hyperplasia and smooth muscle cell proliferation in 
injured arteries {2225}, and impaired angiogenesis and tumor growth {2337}.  
A central function for perlecan in cardiovascular development and angiogenesis has been 
recently demonstrated in the zebrafish Danio rerio. Morpholino-mediated knockdown targeting 
three separate regions of the perlecan mRNA showed relatively normal development of axial 
vessels, dorsal aorta and posterior cardinal vein, but a blunted and anomalous development of the 
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angiogenic vessels, intersegmental and dorsal longitudinal anastomotic vessels (Figure 2 A,B.) 
{3368}. Notably, the perlecan morphant phenotype could be rescued by microinjecting human 
perlecan into single-cell embryos. The overall phenotype of the perlecan morphants is similar to 
that evoked by null mutations or knockdown of VEGFR2 {2970, 3126}, phospholipase Cγ-1, a 
major downstream target of VEGF/VEGFR angiogenic signaling {2975}, receptor blockade by the 
small molecule SU5416 {2940}, or by antisense knockdown of VEGF {2913}. Thus, it is possible 
that perlecan is required for the proper targeting of VEGF to its cognate receptor during 
developmental angiogenesis.   
 In hepatoblastoma xenografts, VEGF is deposited in the same perivascular pattern as tumor-
derived perlecan {3283} and the vascular recovery following VEGF blockade by systemic delivery 
of  soluble VEGFR1 and VEGFR2 is mediated by enhanced expression of perlecan at such 
locations. Concurrently, there is an increase in heparanase in the perivascular zones. Perlecan-
bound VEGF might be dynamically regulated by heparanase-mediated release from the HS chains 
of perlecan {2395} and/or by proteolytic processing of perlecan protein core with ultimate release of 
domain I-associated HS/VEGF complexes in a similar way to that shown previously for domain I-
associated FGF complexes {603}. Thus, sequestration and release of perlecan-bound VEGF in the 
tumor microenvironment represents a mechanism for continuous vessel growth and tumor 
progression. The net result is a protracted activation of VEGFR2 which caused a sustained 
activation of the Akt pathway promoting survival and angiogenesis {3283}.  
 Interestingly, HSPGs can also act across cells or “in trans” {3104}, and specifically can 
potentiate in trans VEGFR-mediated angiogenesis {3103}. Arteries and arterioles are surrounded 
by mural cells, either vascular smooth muscle cells for large arteries and veins or pericytes for 
capillaries. Mural cell HSPGs, most likely including perlecan which is a major product of smooth 
muscle cells/pericytes {144}, can transactivate VEGFR2 on endothelial cells by enhancing signal 
transduction and by facilitating the formation of receptor-ligand complexes on endothelial cells 
{3103}. Thus, perlecan occupies a central role in angiogenesis because it can potentially mediate 
not only the VEGF/VEGFR axis but also the transactivation of smooth muscle cells/pericytes during 
angiogenesis.   
While the overwhelming majority of the reports supports a pro-angiogenic activity of the parent 
perlecan proteoglycan, two studies suggest the possibility that perlecan might inhibit tumor growth 
and angiogenesis. In human fibrosarcoma {901} and Kaposi sarcoma {1693} cells, antisense 
suppression of perlecan increases cell migration and invasion of extracellular matrix, and 
stimulates tumor growth.  
 These apparently contradicting data could be reconciled by considering the fact that perlecan 
acts in a cell context-specific manner. In the vast majority of epithelial tumors (i.e., cancers), 
perlecan may be required for presenting FGF2 and VEGF to the expanding tumor vasculature, 
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whereas in sarcomas perlecan might be inhibitory via the liberation of cryptic anti-angiogenic 
fragments (see next section).  
 
C-terminal portions of basement membrane proteoglycans with angiostatic activity  
A general theme is emerging from a vast body of literature. The key concept is that processing of 
extracellular matrix proteins, and especially those derived from basement membranes, is a 
carefully orchestrated process that can affect either positively or negatively the growth of cells and, 
in particular, angiogenesis { 2647,3365, 3150}. 
Endostatin─ 
Cathepsin L, a cysteine protease of the papain superfamily, cleaves collagen XVIII in the hinge 
region of the NC1 domain (Fig. 2), thereby liberating endostatin, a strong anti-angiogenic factor 
{1705}. Efficient endostatin generation requires a moderately acidic pH, a typical feature of the 
tumor microenvironment {705}. Notably, apoptotic endothelial cells secrete cathepsin L which, in 
turn, cleaves endorepellin near its C-terminal region thereby liberating endorepellin’s angiostatic 
LG3 domain {3422} Thus, cathepsin L and BMP1/Tolloid-like proteases acting in concert could 
liberate LG3 from the perlecan associated with the cell surface or embedded within the basement 
membrane. Finally, cathepsin L has been recently shown to be a key enzyme required for the 
conversion of proheparanase into an active heparanase by specifically cleaving multiple sites 
within the linker region {3423}. Thus, differential expression of cathepsin L may have opposite 
effects on angiogenesis by generating either anti-angiogenic factors (endostatin and endorepellin’s 
LG3) or pro-angiogenic factors (FGF, VEGF, PDGF etc.) via heparanase-mediated cleavage of the 
HS chains of perlecan and collagen XVIII. The molecular understanding of this fine balance 
between pro- and anti-angiogenic activities will undoubtedly lead to a better treatment of cancer 
and other diseases where angiogenesis is predominant. 
 
Endorepellin─The discovery of endorepellin was serendipitous. In a search for novel proteins 
interacting with perlecan’s domain V using the yeast two-hybrid system, a clone was identified that 
contained the C-terminal portion of collagen XVIII, including endostatin {1914}. It was readily 
discovered that perlecan’s domain V blocked HUVEC migration through a collagenous network. 
Thus, this fragment was named “endorepellin” to signify its angiostatic function. Endorepellin is 
active at nanomolar concentrations in a variety of in vitro and in vivo angiogenic assays {1914}.  
The biological interaction between endorepellin, specifically the second globular domain (LG2), 
and endostatin is complex and each appears to neutralize the other’s activity {1914}. In mouse 
basement membranes endostatin colocalizes with perlecan domain V/endorepellin {1915}. Thus, a 
likely function for this protein-protein interaction is a role in basement membrane assembly during 
development {2562}. The terminal LG3 domain of endorepellin appears to contain most of its 
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angiostatic activity {2221}. Notably, BMP-1/Tolloid-like proteinases cleave endorepellin at a specific 
single site, between Asn4196 and Asp4197, thereby generating intact LG3 from the parent molecule 
(Fig. 2) {2424}. The sequence around the cleavage site is highly conserved across species, and 
mutation of Asp4197 into Ile prevents processing of endorepellin. 
During a search for perlecan binding partners using the yeast two-hybrid system and domain V of 
perlecan as the bait, we isolated a highly interactive cDNA clone which encoded the NC1 domain 
of collagen type XVIII {1914} comprising the powerful anti-angiogenic fragment named endostatin 
{1298}. It was soon realized that domain V of the perlecan protein core harbored a powerful 
angiostatic activity as demonstrated by various in vitro and in vivo angiogenic assays; this region 
was renamed endorepellin to designate its intrinsic anti-endothelial activity {1914}. Endorepellin 
interacts specifically with the α2β1 integrin receptor in platelets {2991} and endothelial cells {2221} 
and, in the latter, triggers a signaling cascade that leads to disruption of the endothelial actin 
cytoskeleton (Figure 2 C-H) and thus to cytostasis {2221, 2647, 2432, 2316}. Using a proteomic 
approach, several key proteins involved in angiogenesis including β-actin were significantly down-
regulated by exposing endothelial cells to recombinant endorepellin {3281}. Importantly, systemic 
delivery of human recombinant endorepellin to tumor xenograft-bearing mice causes a marked 
suppression of tumor growth and metabolic rate mediated by a sustained down-regulation of the 
tumor angiogenic network {2990}.  Genetic analysis using siRNA-mediated block of endogenous 
α2β1 integrin or animals lacking the α2β1 integrin receptor have definitively shown that this is a 
key receptor for endorepellin, and thus for perlecan protein core, and have further demonstrated 
that endorepellin targets the tumor xenograft vasculature in an α2β1 integrin-dependent manner 
{3219}. Interestingly, endorepellin has been detected as a released product in the upper 
proliferating zone of fetal growth plate {3222} suggesting that cartilage endorepellin might 
counteract blood vessel invasion in cartilage. The take-home message is that endorepellin might 
represent a member of the family of cryptic domains residing within larger parent molecules of the 
extracellular microenvironment that act in a dominant negative manner. Other processed 
fragments of extracellular matrix proteins have recently been described and shown to interact with 
distinct integrin receptors {2719}. 
Notably, the last laminin-like globular domain, LG3 (Fig. 2), possesses most of the biological 
activity {2221} and can be released from the parent molecule by BMP-1/Tolloid-like 
metalloproteinases {2424} which recognize an ND dipeptide which is highly conserved across 
species including human, mouse, Drosophila and zebrafish {3368}. This highly-conserved region 
within the perlecan protein core together with the high conservation of BMP-1/Tolloid-like 
metalloproteinases suggests that liberation of LG3 might be of physiological importance. Mutations 
in LG3 producing molecules with lower or no affinity for calcium {2424} disrupt LG3 angiostatic 
activity. It is noteworthy that the proximal two globular domains of endorepellin, LG1 and LG2, 
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might be occupied by a number of high-affinity ligands such as dystroglycan and endostatin within 
basement membranes and on cell surfaces {2432, 2316}. In contrast, LG3 might be relatively 
accessible and thus likely to be released by partial proteolysis, a process that is common to most 
LG domains of laminin {1784, 2234, 1898}. 
Over a decade ago, Oda et al {771} reported the presence of perlecan’s LG3 fragments in the 
urine of end-stage renal failure patients . The LG3 fragments had N-terminal residues (i.e., cleaved 
by BMP-1/Tolloid-like metalloproteinases) identical to those found in endothelial cells by us. 
Following this initial observation, a number of investigators have detected LG3 in several 
pathological conditions (Table 1). For instance, similar LG3 fragments have been found elevated in 
the urine of patients with chronic allograft nephropathy {2634}, and in the amniotic fluid of pregnant 
women {3351} with a marked increase in women with symptoms of premature rupture of fetal 
membranes {2098, 2662} and those carrying trisomy 21, Down syndrome, fetuses {3023}. In 
addition, endorepellin fragments have been detected in normal human blood {2200}, in the urine of 
children with sleep apnea {3437} and in the media conditioned by apoptotic endothelial cells {2231, 
2618}. In endothelial cells, the released LG3 interacts with the α2β1 integrin receptor of fibroblasts 
and triggers a signaling cascade that leads to activation of an anti-apoptotic pathway and 
potentially to a fibrogenic response {2900}. In fibrotic diseases, endothelial cell apoptosis precedes 
the recruitment of fibroblasts, and thus release of LG3 could affect not only angiogenesis, but also 
the production of collagen and the overall sclerotic response.  This is another example of cell-
specific context in which cryptic perlecan fragments might exert diverse effects.  
LG3 is also found in the secretome of pancreatic and colon carcinoma cells {2864,2424}. 
Finally, circulating LG3 levels are reduced in patients with breast cancer suggesting that reduced 
titers might be a useful biomarker for cancer progression and invasion. The significance of LG3 
appearance in all of these conditions is not clear but a possibility is that LG3 might represent a sign 
of vascular injury or a biomarker for the high turnover rate of malignant cells.  
We propose that endorepellin/LG3 is liberated via partial proteolysis during tissue remodeling 
and cancer growth thereby representing an additional layer of control for angiogenesis, which also 
depends on the cellular context and specific integrin expression {2647}. One possibility is that 
tumor growth might be enhanced in vivo by a lack of circulating LG3.  Although this is an 
unanswered question, recent studies using α2β1 integrin-null mice have reported an increased 
angiogenesis in the granulation tissue of wounded animals {2992, 2993}. Tumor angiogenesis is 
dependent on the “cancer cell context“ in α2β1 integrin-null animals further corroborating the  
importance of cross-talk between the invading cancer cells and the tumor microenvironment 
{3333}.  
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An endorepellin-like structure in agrin─Agrin harbors an endorepellin-like domain at its C-
terminus (Fig. 2). This domain comprises three LG modules interspersed by three EGF-like repeats 
{2208}. Notably, endorepellin-like and LG3 fragments are generated from agrin by a specific serine 
protease, neurotrypsin {3380}. Neurotrypsin cleaves agrin at two homologous sites liberating a 90-
kDa fragment and the C-terminal globular domain, LG3 {3380}. The release of cryptic fragments 
within agrin could promote interactions with other proteins and receptors that were inaccessible to 
full-length agrin {3380}. While there is no evidence that any of these modules affect angiogenesis, 
there is ample evidence that they play important biological roles and can also mediate signaling 
events propagated from surface receptors. For example, the endorepellin-like region of agrin is 
involved in binding to dystroglycan and integrins {3382, 2208}. In addition, the LG3 module of agrin 
signals through a synaptic receptor that has been recently identified as the Na+-K+-ATPase {3381}. 
Agrin LG3 inhibitory activity evokes membrane depolarization and increases action potential in 
neurons by interacting with the α3 subunit of the Na+-K+-ATPase, a member of the family of ion 
pumps {3381}. A mini-agrin gene composed of the N-terminus (which binds to laminin γ1) and the 
C-terminal endorepellin-like structure (which binds to α-dystroglycan) can function as a biological 
linker and can ameliorate muscular dystrophy caused by mutation in the laminin α2 gene {3062}. 
Interestingly, chimeric proteins composed of the N-terminus of agrin and the mouse endorepellin 
can also have similar linker/stabilizing activity and rescue the dystrophic phenotype {3062}. A 
miniaturized form of agrin, consisting of the lamini-binding and MuSK-activating domains, can 
restore neuromuscular junction in agrin mutant mice when expressed by developing muscle 
{3644}.  It is, therefore, possible that LG-containing modules interspersed by EGF-like repeats, 
such as those present in perlecan and agrin, could serve unique cell- and tissue-specific functions. 
Not surprisingly, these modules have been conserved for over 500 million years of evolution. 
Utilization of endorepellin-like structures which bind with high affinity to surface receptors such α-
dystroglycan and α2β1 integrin might be utilized in the future for the treatment of diseases in which 
these two receptors are involved. 
 
 
 
 
A WORKING MODEL OF PERLECAN’S ROLE IN TUMOR ANGIOGENESIS 
Extracellular matrix-derived signals control vascular morphogenesis and remodeling {2070, 2717, 
3365}. Growth factors such as FGF and VEGF require not only their receptors for full biological 
activity, but they also require essential co-factors such as HS and, indirectly, the protein core of 
perlecan and other extracellular HSPGs. Thus, perlecan functions in targeting, storage and 
delivery of growth factors to their functional receptors.  It has been recently proposed that complex 
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molecules such as perlecan, which reaches 100–200 nm in length, could serve to cluster various 
ectodomains of transmembrane proteins, stabilize their interactions and thus create a stable 
“signalosome” {3149}. During tumor progression, the vascular basement membrane undergoes 
constant remodeling {2070} and when heparanase is preponderant {2395} it could release growth 
factors from the HS chains of perlecan (Figure 4). These increased levels of growth factors 
together with the cofactor HS would activate their respective cognate receptors which, in turn, 
would activate the pro-survival activity of Akt and ultimately promote angiogenesis and tumor 
progression.  Obviously, marked proteolysis would also generate a large number of growth factors 
and cytokines that are bound to the protein core including PDGF, FGF7, and FGF2. When 
proteolysis is somewhat “limited”, endorepellin and LG3 could be liberated in the tumor 
microenvironment to counteract the FGF/FGFR and VEGF/VEGFR2 axes: endorepellin interacts 
with the α2β1 integrin receptor and triggers a signaling cascade that leads to disruption of the 
endothelial cell actin cytoskeleton, inhibition of cell motility, and ultimately inhibition of 
angiogenesis and concurrent tumor suppression (Figure 4). This conceptual framework could be 
easily applied to other endogenous inhibitors of angiogenesis associated with the basement 
membrane, such as collagen XVIII, which is also an HSPG and contains at its C-terminus 
endostatin {2946}, and collagen IV which contains tumstatin {2719}. 
 Understanding the balance between pro- and anti-angiogenic cues would be of great 
therapeutic potential in the future. Would blocking heparanase, for instance, be a suitable 
treatment for certain forms of highly vascularized cancers? What protease inhibitors would be most 
beneficial for tilting the balance toward a less vascularized or avascular condition? Should heparin 
mimetics be used in tumor therapy to cause the diffusion of growth factors away from the tumor 
cells? Would combination therapy work? These important questions can conceivably be answered 
in the near future after we elucidate the role each component exerts in the complex processes of 
vascular generation, regression and remodeling that occur during cancer evolution. 
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FIGURE LEGENDS 
Fig. 1. Structural domains of human perlecan, agrin and collagen XVIII.  The five domains of 
perlecan are in Roman numerals from the N- to the C-terminus.  The other domains of agrin and 
collagenXVII are listed or detailed in the text.  
 
Fig. 2.  Schematic representation of the C-termini of perlecan, agrin and collagen XVIII (left) and 
their respective cognate receptors (right).  Also annotated are the locations of various proteases 
generating intact modules or fragments thereof from the three polypeptides. 
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 Table 1.  Presence of perlecan’s LG3 module in various tissues and biological fluids, and potential 
functional implications.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Location Condition Functional Implication Reference 
Urine End-stage renal 
disease 
Biomarker for vascular 
injury 
{771} 
Urine Chronic allograft 
nephropathy 
Biomarker for immune-
mediated vascular injury  
{2634} 
Amniotic fluid Premature rupture 
of fetal membranes 
Biomarker for fetal 
ischemia and vascular 
injury 
{2098, 2662} 
Amniotic fluid Mothers carrying 
Down Syndrome 
fetuses 
Biomarker for abnormal 
fetal development and 
vascular injury 
{3023} 
Blood Normal subjects 
and breast cancer 
patients 
Reduced in breast 
cancer patient:s; role as 
anti-angiogenic factor 
{3289} 
Secreted by 
endothelial cells 
Endothelial cells 
undergoing 
apoptosis 
Potential function as a 
paracrine inducer of 
fibrosis 
{2231, 2618, 2900} 
Secreted by various 
cancer cells 
Pancreatic and 
colon carcinoma  
cells  
Potentially linked to the 
highly turnover rate of 
transformed cells 
{2864, 2424} 
Urine Children with sleep 
apnea 
Potential biomarker of 
transient brain ischemia 
{3437} 
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